Metabolic Targeting Partnerships ImmunoMet's lead IM156 inhibits PC1 and blocks the oxidative phosphorylation pathway, aligning with pharma players pursuing metabolism-targeted cancer and fibrotic therapies. With Phase 1 completed and Phase 2 PoC in IPF in planning, there is an opportunity to pursue license or co development deals to advance late stage studies while sharing development risk. Target biotech and pharma partners seeking to augment fibrosis or oncology pipelines with novel mitochondrial metabolism inhibitors.

IPF PoC Focus IPF focused PoC presents a clear partnership angle for respiratory and antifibrotic portfolios. Potential partners include firms seeking entry into fibrosis with metabolism targeted modalities; explore co development or licensing arrangements to accelerate IPF trials, leveraging ImmunoMet's clinical data and first in human work. Consider offering preferred access or option deals to run Phase 2 more rapidly, with partner funding and manufacturing support.

Pancreatic Cancer Synergy Recent news shows a Phase 1b study of IM156 in combination with gemcitabine and nab paclitaxel in advanced pancreatic cancer, creating a practical entry point for oncology partnerships. Approach big pharma and mid sized oncology players with pancreatic cancer programs or metabolic inhibitors about co development or licensing to expand into combination therapies and additional tumor types where OXPHOS inhibition may help. Position as a collaboration to de risk upfront investment through shared development costs.

Lean Ops Partnerships ImmunoMet operates with a lean team (2-10 employees), indicating a strong need for outsourced clinical operations, CMC, regulatory, and manufacturing support. Build a portfolio of CROs and CMOs and packaged services to accelerate milestones, ensure GMP supply for IM156, and streamline regulatory filings, enabling faster path to value creation for a partner.

Funding Momentum Multiple financings since spin off and ongoing investor interest signal strategic value of IM156. Use this momentum to engage with strategic investors and potential acquirers for a full or partial license or acquisition, emphasizing IM156's novel PC1 inhibition, planned IPF PoC trajectory, and expanding oncology exploration.